Peptides for Healing
Research overview of peptides studied for tissue healing, wound repair, and regeneration. BPC-157, TB-500, and regenerative peptide evidence.
Research Overview
Healing peptides represent a diverse research category spanning wound repair, tissue regeneration, and recovery from injury. The most frequently discussed peptides in this space—BPC-157 and TB-500—have extensive preclinical data but limited human clinical trial evidence.
BPC-157 (Body Protection Compound-157) originates from gastric juice proteins and has been studied in numerous rodent models for tendon, muscle, ligament, and gastrointestinal healing. However, most published research comes from a single research group, raising concerns about independent replication.
TB-500, a fragment of thymosin beta-4, has been studied for wound healing applications. The parent compound (Tβ4) has more extensive research, while the specific fragment marketed as TB-500 has fewer direct studies. Both BPC-157 and TB-500 remain unapproved and are prohibited in sport.
Key Peptides in Healing Research
Body Protection Compound (BPC-157)
Status: Not approved by any regulatory agency
| Research Type | Evidence Level |
|---|---|
| Rodent models | Extensive |
| Human trials | Limited (1-2 small studies) |
| Independent replication | Limited |
Proposed mechanisms: VEGF modulation, nitric oxide system, anti-inflammatory effects
Thymosin Beta-4 / TB-500
Status: Not approved (Tβ4 has some clinical development)
| Research Type | Evidence Level |
|---|---|
| Tβ4 human research | Moderate |
| TB-500 specific | Low |
| Wound healing models | Moderate |
Proposed mechanisms: Actin sequestration, cell migration, anti-inflammatory
GHK-Cu (Copper Peptide)
Status: Available in cosmetic formulations
Primarily studied for skin wound healing and collagen synthesis. Better evidence base for topical applications than systemic use.
Evidence Limitations
Researchers should note:
- Most healing peptides lack Phase 3 clinical trials
- BPC-157 research concentration from single source
- TB-500 often extrapolated from Tβ4 studies
- All are prohibited by WADA in sport
Peptides Studied for Healing
GHK
ModerateA naturally occurring tripeptide (Gly-His-Lys) with copper-binding affinity and wound healing properties. The base form of GHK without added copper. Endogenous to human plasma where it circulates bound to copper. Declines with age. Most research focuses on the copper-complexed form (GHK-Cu), making evidence for GHK alone limited. Primarily relevant as the precursor to GHK-Cu.
BPC-157
LowBPC-157 is a synthetic gastric-peptide fragment with extensive preclinical literature but small, heterogeneous human evidence: three full primary reports and two controlled study groups reported only in meeting abstracts. It has no FDA-approved formulation or validated clinical regimen.
GHK-Cu
LowGHK-Cu is the copper complex of the GHK tripeptide. Cell and animal studies support matrix-remodeling mechanisms, while small topical human studies give mixed results; these findings do not establish injected GHK-Cu efficacy or safety.
LL-37
LowLL-37 is the active human cathelicidin peptide. Three topical wound trials studied native LL-37, with mixed outcomes; an oral trial used engineered bacteria expressing LL-37. These results do not establish systemic benefit.
TB-500
Very LowTB-500 commonly denotes N-acetyl-LKKTETQ, a seven-residue fragment of thymosin beta-4. Full-length thymosin beta-4 trial results do not establish this fragment's efficacy or safety. No human TB-500 exposure data were identified in FDA's compounding review.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.